Integrin-linked kinase inhibitors
US8658647B2 · kind B2 · utility
0Cited by
6References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 21, 2011 |
| Grant date | Feb 25, 2014 |
| Priority date | — |
| Expiry date | Nov 21, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D231/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A number of compounds and use of the compounds in a method for treating or preventing cancer in a subject by administering to the subject a pharmaceutical composition including a compound of formula I or a pharmaceutically acceptable salt thereof are described.The compounds can also be used to inhibit integrin-linked kinase in a cell, which has an effect on the Akt signaling pathway.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.